全文获取类型
收费全文 | 11040篇 |
免费 | 126篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 1095篇 |
妇产科学 | 367篇 |
基础医学 | 947篇 |
口腔科学 | 327篇 |
临床医学 | 464篇 |
内科学 | 2847篇 |
皮肤病学 | 354篇 |
神经病学 | 458篇 |
特种医学 | 270篇 |
外科学 | 2494篇 |
综合类 | 79篇 |
现状与发展 | 2篇 |
预防医学 | 480篇 |
眼科学 | 270篇 |
药学 | 330篇 |
中国医学 | 64篇 |
肿瘤学 | 289篇 |
出版年
2023年 | 37篇 |
2022年 | 58篇 |
2021年 | 226篇 |
2020年 | 101篇 |
2019年 | 1468篇 |
2018年 | 1104篇 |
2017年 | 617篇 |
2016年 | 84篇 |
2015年 | 102篇 |
2014年 | 140篇 |
2013年 | 127篇 |
2012年 | 51篇 |
2011年 | 78篇 |
2010年 | 50篇 |
2009年 | 66篇 |
2008年 | 50篇 |
2007年 | 47篇 |
2006年 | 54篇 |
2005年 | 43篇 |
2004年 | 33篇 |
2003年 | 29篇 |
2002年 | 27篇 |
2001年 | 31篇 |
2000年 | 32篇 |
1999年 | 35篇 |
1998年 | 20篇 |
1997年 | 20篇 |
1996年 | 9篇 |
1995年 | 7篇 |
1994年 | 13篇 |
1993年 | 4篇 |
1992年 | 6篇 |
1991年 | 10篇 |
1989年 | 4篇 |
1987年 | 3篇 |
1986年 | 5篇 |
1985年 | 516篇 |
1984年 | 789篇 |
1983年 | 453篇 |
1982年 | 634篇 |
1981年 | 551篇 |
1980年 | 455篇 |
1979年 | 518篇 |
1978年 | 432篇 |
1977年 | 404篇 |
1976年 | 487篇 |
1975年 | 417篇 |
1974年 | 361篇 |
1973年 | 367篇 |
1972年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
4.
ObjectiveThe purpose of this paper is to review the efficacy and safety profile in children treated with topical 0.03% Tacrolimus ointment for vernal keratoconjunctivitis in Middle East and to propose a treatment posology. According to recent studies, a complex non-IgE dependent mechanism plays a relevant role in the pathogenesis of vernal keratoconjunctivitis. Numerous cells and mediators have been found in the serum, conjunctiva and tears of patients with Vernal keratoconjunctivitis.DesignThis case series included 10 patients from a single centre, pediatric department of a tertiary hospital with active symptomatic vernal keratoconjunctivitis. All the patients had proliferative lesions and corneal involvement despite conventional medications, including topical steroids. All other medications, systemic and topical: steroids, antihistamines and cyclosporine, were unsuccessful. Patients were treated with topical 0.03% Tacrolimus ointment twice daily for 8 weeks and then once a day for the next two month followed by thrice a week for two months. The changes in symptoms and signs after treatment were evaluated, also the development of possible complications was assessed.ResultsThe results showed a significant reduction in signs and symptoms after 4 weeks of the treatment. Clinical resolution of giant papillae and corneal lesions were seen within eight weeks and no additional drug was required during that period, except tear substitutes. Treatment was continued for period of two months and then slowly reduced.ConclusionThe use of 0.03% Tacrolimus ointment is safe and effective in children refractory to conventional treatment of vernal keratoconjunctivitis even in high temperature climate as Middle East. Due to the effectiveness of the treatment, the dosage used may be proposed for conventional use. 相似文献
5.
6.
近代著名外交家、法学家伍廷芳撰写了一部养生学著作《延寿新法》,其版本众多,以南京中医药大学图书馆馆藏抄本为善。《延寿新法》一书从生理、饮食、睡眠、阳光、衣着、气象、风俗、烟酒、运动等方面详论养生延年之法。在“西学东渐”的时代背景下,《延寿新法》的养生思想折射出中西医交流的历史痕迹。 相似文献
7.
8.
9.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献
10.